Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Drug Toxicity: Dose-Dependent Reactions

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

Drug Toxicity: Allergic Reactions

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Surgical Therapy for Lung Cancer: Why it Should be Performed in High Volume Centres].

Pneumologie (Stuttgart, Germany)·2020

Same author

[Drug-induced pulmonary diseases].

Der Pneumologe·2020

Same author

[Pathological-anatomical diagnosis according to the German lung cancer guideline 2018].

Der Pathologe·2018

Same author

Long-term symptom improvement and patient satisfaction after AV-node ablation vs. pulmonary vein isolation for symptomatic atrial fibrillation: results from the German Ablation Registry.

Clinical research in cardiology : official journal of the German Cardiac Society·2018

Same author

Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Same author

[Management of Lung Abscess].

Zentralblatt fur Chirurgie·2015

Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020

Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020

Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020

Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016

Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016

Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2014

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 22, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

[Amiodarone-induced pulmonary toxicity].

A Heisel¹, M Berg, M Stopp

¹Innere Medizin III, Medizinische Universitätsklinik, Homburg.

Medizinische Klinik (Munich, Germany : 1983)

|May 30, 2009

Summary

This summary is machine-generated.

Amiodarone effectively treats heart rhythm disorders but can cause serious lung damage. Early diagnosis and stopping the drug are key, with steroids offering life-saving support in severe cases.

More Related Videos

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Related Experiment Videos

Last Updated: Jun 22, 2026

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Zebra II as A Novel System to Record Electrophysiological Signals in Zebrafish

Published on: August 16, 2024

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Area of Science:

Cardiology
Pulmonology
Pharmacology

Context:

Amiodarone is a vital antiarrhythmic medication.
Pulmonary toxicity is a significant adverse effect of amiodarone.
The exact mechanisms of amiodarone-induced lung injury remain unclear.

Purpose:

To summarize the current understanding of amiodarone-induced pulmonary toxicity.
To outline the clinical presentation, diagnosis, and management strategies.
To highlight the importance of monitoring for and managing this adverse reaction.

Summary:

Amiodarone effectively controls ventricular and supraventricular tachyarrhythmias.
Pulmonary toxicity, including interstitial pneumonitis and fibrosis, is the most severe adverse reaction.
Lower maintenance doses (≤300 mg/d) are associated with reduced incidence.
Diagnosis is often by exclusion, with no reliable predictors identified.
Management involves drug withdrawal and, in severe cases, corticosteroid therapy.

Impact:

Informs clinicians about the risks associated with amiodarone therapy.
Aids in the early recognition and management of pulmonary toxicity.
Emphasizes the need for careful patient monitoring and dose adjustment.
Highlights the potential for life-saving interventions in severe cases.